Combined targeting of Arf1 and Ras potentiates anticancer activity for prostate cancer therapeutics

BACKGROUND: Although major improvements have been made in surgical management, chemotherapeutic, and radiotherapeutic of prostate cancer, many prostate cancers remain refractory to treatment with standard agents. Therefore, the identification of new molecular targets in cancer progression and develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Lang, Liwei, Shay, Chloe, Zhao, Xiangdong, Teng, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568197/
https://www.ncbi.nlm.nih.gov/pubmed/28830537
http://dx.doi.org/10.1186/s13046-017-0583-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568197/
https://www.ncbi.nlm.nih.gov/pubmed/28830537
http://dx.doi.org/10.1186/s13046-017-0583-4

Ejemplares similares